Skip to main content

Table 1 Baseline characteristics for 25 participants switched to DTG

From: Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda

Characteristic N (%) or Median (IQR)
Age, years 35 (30—40)
Duration on ART prior to DTG switch, months 67 (51—125)
Duration on DTG after switching, months 16 (10—18)
Gender  
 Female 17 (68)
 Male 8 (32)
History of toxicity  
 Stable on DTG 1 (4)
 No history of toxicity 18 (72)
 Experienced toxicities 6 (24)
Education level, years  
 Never been to school (illiterate) 3 (12)
 Primary (≤ 7) 5 (20)
 Secondary (8–13) 9 (36)
 Post-secondary (> 13) 8 (32)
Marital status  
 Married/living with partner 14 (56)
 Separated/divorced 1 (4)
 Single 7 (28)
 Widowed 3 (12)
WHO stage  
 Stage 1 5 (20)
 Stage 2 7 (28)
 Stage 3 7 (28)
 Stage 4 6 (24)
Adherence history  
 Good adherence (took drugs daily and on time) 20 (80)
 Poor adherence (failed to take drugs daily and or on time) 5 (20)
  1. IQR interquartile range